Literature DB >> 17766656

Evolving strategies for combined-modality therapy for locally advanced head and neck cancer.

Marshall Posner1.   

Abstract

Despite continual advances in the treatment of head and neck cancer, disease-free survival, functional outcome, toxicity of therapy, and overall survival remain less than optimal. While traditional treatment has focused on surgical resection with or without radiation and chemoradiotherapy, newer combined-modality regimens may offer patients a better prognosis, organ preservation, and less morbidity. In this paper, single agents and doublet therapy are reviewed, as are emerging data on the utility of induction therapy, chemoradiotherapy, and surgery as a sequential treatment regimen. Disclosure of potential conflicts of interest is found at the end of this article.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17766656     DOI: 10.1634/theoncologist.12-8-967

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  7 in total

1.  Combined-modality treatment in advanced oral squamous cell carcinoma: Primary surgery followed by adjuvant concomitant radiochemotherapy.

Authors:  Matthias Kreppel; Uta Drebber; Hans-Theodor Eich; Timo Dreiseidler; Joachim E Zöller; Rolf-Peter Müller; Martin Scheer
Journal:  Strahlenther Onkol       Date:  2011-03-14       Impact factor: 3.621

Review 2.  Balancing risk and reward in target delineation for highly conformal radiotherapy in head and neck cancer.

Authors:  Avraham Eisbruch; Vincent Gregoire
Journal:  Semin Radiat Oncol       Date:  2009-01       Impact factor: 5.934

Review 3.  Chemoselection: a paradigm for optimization of organ preservation in locally advanced larynx cancer.

Authors:  Jeffrey M Vainshtein; Vivian F Wu; Matthew E Spector; Carol R Bradford; Gregory T Wolf; Francis P Worden
Journal:  Expert Rev Anticancer Ther       Date:  2013-09       Impact factor: 4.512

Review 4.  Induction chemotherapy for locoregionally advanced head and neck cancer: past, present, future?

Authors:  Glenn J Hanna; Robert I Haddad; Jochen H Lorch
Journal:  Oncologist       Date:  2013-02-26

5.  A phase I clinical study of VB4-845: weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck.

Authors:  Glen C MacDonald; Michèle Rasamoelisolo; Joycelyn Entwistle; Jeannick Cizeau; Denis Bosc; Wendy Cuthbert; Mark Kowalski; Maureen Spearman; Nick Glover
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

6.  MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer.

Authors:  George Fountzilas; Anna Kalogera-Fountzila; Sophia Lambaki; Ralph M Wirtz; Angelos Nikolaou; Georgia Karayannopoulou; Mattheos Bobos; Vassiliki Kotoula; Samuel Murray; Alexandros Lambropoulos; Gerasimos Aravantinos; Konstantinos Markou; Eleni Athanassiou; Despina Misailidou; Konstantine T Kalogeras; Demosthenis Skarlos
Journal:  J Oncol       Date:  2009-12-29       Impact factor: 4.375

7.  Role of paclitaxel and platinum-based adjuvant chemotherapy in high-risk penile cancer.

Authors:  Vanita Noronha; Vijay Patil; Vikas Ostwal; Hemant Tongaonkar; Ganesh Bakshi; Kumar Prabhash
Journal:  Urol Ann       Date:  2012-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.